Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2013)
30 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 27, 2013
Slide 1: Annual Shareholders' Meeting 2013
Annual Shareholders’ Meeting 2013 27 August 2013 Fisher & Paykel HEALTHCARE
Slide 2: Tony Carter - Chairman
Tony Carter - Chairman 1 Fisher &.Paykel HEALTHCARE
Slide 3: Your Board
Your Board Tony Carter Michael Daniell Nigel Evans Roger France Lindsay Gillanders i= = mae q@ am Geraldine McBride = Arthur Morris Donal O’Dwyer Gary Paykel Fisher & Paykel 2 HEALTHCARE
Slide 4: Agenda
Agenda i CHAIR’S ADDRESS MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER’S REVIEW FINANCIAL STATEMENTS RESOLUTIONS VOTING GENERAL QUESTIONS Fisher & Paykel 3 HEALTHCARE
Slide 5: Improving Patient Care and Outcomes
Improving Patient Care and Outcomes Fisher & Paykel 4 HEALTHCARE
Slide 6: 2013 Financial Highlights
2013 Financial Highlights rr N2$ 771m 20% *% N7$556.3m RECORD NET PROFIT GROWTH IN NET PROFIT RECORD OPERATING AFTER TAX AFTER TAX REVENUE Fisher & Paykel 5 HEALTHCARE
Slide 7: Growth
Growth 17 =~ OPERATING REVENUE OPERATING PROFIT OPERATING REVENUE OPERATING PROFIT NZ$ MILLIONS NZ$ MILLIONS NZ$ MILLIONS NZ$ MILLIONS ™ nN s + J N i 2 % a fo) in N § 2 ” S © ae N = = a a 2 ¢ o od N » : + g | | | » 11 12 13 11 12 13 "1 12 13 1 12 aK Reported Constant Currency Fisher & Paykel 6 HEALT
Slide 8: Dividend
Dividend 2 12.4 cps 43 TOTAL DIVIDEND PARTICIPATION IN FOR THE YEAR FULLY DIVIDEND REINVESTMENT IMPUTED PLAN FOR FINAL DIVIDEND Fisher & Paykel 7 HEALTHCARE
Slide 9: _ — o =
_ — o =
Slide 10: Your Board
Your Board Tony Carter Michael Daniell Nigel Evans Roger France Lindsay Gillanders i= = mae q@ am Geraldine McBride = Arthur Morris Donal O’Dwyer Gary Paykel Fisher & Paykel 9 HEALTHCARE
Slide 11: Fisher & Paykel
Fisher & Paykel 10 HEALTHCARE
Slide 12: Michael Daniell - MD & CEO
Michael Daniell - MD & CEO re Fisher & Paykel 1 HEALTHCARE
Slide 13: Growth Strategy
Growth Strategy CONTINUOUS PRODUCT IMPROVEMENT “4 {i SERVE MORE PATIENT GROUPS 3 MORE PRODUCTS FOR EACH PATIENT AGF INCREASE OUR INTERNATIONAL PRESENCE 12 Fisher& Paykel HEALTHCARE
Slide 14: Research & Development
Research & Development Ss a — — Fisher & Paykel HEALTHCARE
Slide 15: Respiratory & Acute Care (RAC)
Respiratory & Acute Care (RAC) RESPIRATORY & ACUTE CARE Respiratory care is often required for patients during the management of trauma and acute care, and for infants in neonatal care. Fisher &Paykel 14 HEALTHCA a H
Slide 16: RAC New Products
RAC New Products 2 Gai AiRvo"2 Optiflow” junior Fisher & Paykel 15 HEALTHCARE
Slide 17: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) ly ee >) ) naqgage? Tens of millions of people worldwide who have untreated obstructive sleep apnea, stop breathing for short periods many times each night while they sleep. i Fisher &.Paykel HEALTHCARE
Slide 18: OSA New Products
OSA New Products rs ICON"+ Fisher & Paykel 17 HEALTHCARE
Slide 19: Serving More Patients
3 Serving More Patients S-gm Invasive ae Adult Noninvasive Ventilation a a Surgical Invasive Ventilation Neonatal T-Piece Resuscitation Optiflow Junior CPAP Therapy Fisher & Paykel 18 HEALTHCARE
Slide 20: Increase Our International Presence
Increase Our International Presence es REVENUE BY REGION NORTH AMERICA EUROPE MIDDLE EAST SOUTH AMERICA AFRICA @ NORTH AMERICA @ europe @ ASIA-PACIFIC @ OTHER Fisher & Paykel 19 HEALTHCARE
Slide 21: Foreign Exchange Hedging
Foreign Exchange Hedging ee 89% 88% USD EXPOSURE € EXPOSURE HEDGED HEDGED FOR THE FOR THE BALANCE BALANCE OF FY2014 OF FY2014 AT AT AVERAGE RATE OF AVERAGE RATE OF 0.7702 0.4678 44% USD EXPOSURE HEDGED FOR FY2015 AT AVERAGE RATE OF 0.7767 60% € EXPOSURE HEDGED FOR FY2015 AT AVERAGE RATE OF 0.4594 20
Slide 22: Growth in FY2013
Growth in FY2013 2 Full Year Results 12 Months Ended 12 Months Ended 31 March 2012 31March 2013. % Change Operating Revenue (Nz$m) 516.7m 556.3m +7% Operating Revenue (Constant Currency) 467.0m 519.0m +71% RAC Operating Revenue (Constant Currency) +15% OSA Operating Revenue (Constant Currency) +6% F
Slide 23: Accelerating Growth in Second Half
Accelerating Growth in Second Half - = Second Half Results % Change compared to Prior Comparable Period Operating Revenue (Constant Currency) +14% Operating Profit (Constant Currency) +56% RAC Operating Revenue (Constant Currency) +18% OSA Operating Revenue (Constant Currency) +10% Consumables Reven
Slide 24: Increasing Margins
Increasing Margins A 17P=~=~* Product Mix Mexico Lean Logistics & Manufacturing Manufacturing Supply Chain Fisher &Paykel 23 HEALTHCARE
Slide 25: Outlook
Outlook First Half Operating Revenue ~NZ$310 million Net Profit after Tax ~NZ$43 million Full Year Expect at NZD:USD exchange rate of ~0.80 Operating Revenue NZ$625 million - NZ$645 million Net Profit after Tax NZ$90 million - NZ$95 million Fisher & Paykel 24 HEALTHCARE
Slide 26: Summary
Summary ee i ee a | oe te ey Fisher & Paykel 25 HEALTHCARE
Slide 27: Financial Statements
Financial Statements Annual Report 2013 * Opportunity for shareholders to ask any questions specifically on the financial statements, the auditors’ report or the company’s 2013 annual report. ¢ There will be an opportunity to ask any general questions once all items on the agenda have been considere
Slide 28: Voting
Voting ee 0 66 * In respect of each resolution, please tick the “for”, “against” or “abstain” box. * Once you have completed your voting, please place your vote in a ballot box. ¢ Please raise your hand if you require a pen. ¢« Results will be announced to NZSX and ASX as soon as they are available.
Slide 29: Q&A
Q&A Paykel HEALTHCARE Fisher & 28
Slide 30: Annual Shareholders' Meeting 2013
Annual Shareholders’ Meeting 2013 27 August 2013 Fisher & Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (August 2013) on 6ix